Gradle B D
Epstein Becker & Green, Washington, DC.
Physician Exec. 1995 Jan;21(1):28-9.
Antitrust guidelines released September 27 by the Department of Justice (DOJ) and the Federal Trade Commission (FTC) have produced new guidance for providers in three areas and refined six areas that were the subject of last year's statement. Although the agencies have characterized the 1994 Statement as a "landmark," it is more evolutionary than revolutionary in nature--providing clarifications, adjustments, and additions to the 1993 Statement, including an expansion of the safety zone for certain physician joint ventures and a significant discussion of the agencies' framework of review of multi-provider networks. The 1994 Statement is also significant because it appears that it will be the agencies' last formal statement on this issue for some time. Since its release, both DOJ and FTC have stated that no clarifications or expansions to the 1994 Statement are currently planned. This article provides highlights of the new statement. "Health Law" is a regular feature of Physician Executive from the Washington, D.C., law firm Epstein Becker & Green, P.C. Mark Lutes of that law firm serves as editor for the column.
美国司法部（DOJ）和联邦贸易委员会（FTC）于9月27日发布的反垄断指南在三个领域为供应商提供了新的指导意见，并对去年声明所涉及的六个领域进行了细化。尽管这两个机构将1994年的声明定性为“里程碑式的”，但从本质上讲，它更多的是渐进式的而非革命性的——它对1993年的声明进行了澄清、调整和补充，包括扩大了某些医生合资企业的安全区，并对这两个机构审查多供应商网络的框架进行了大量讨论。1994年的声明也很重要，因为它似乎将是这两个机构在一段时间内关于这个问题的最后一份正式声明。自发布以来，DOJ和FTC都表示目前没有计划对1994年的声明进行澄清或扩展。本文重点介绍了这份新声明的要点。“健康法”是华盛顿特区爱泼斯坦·贝克尔·格林律师事务所（Epstein Becker & Green, P.C.）为《医师执行官》（Physician Executive）定期撰写的专题。该律师事务所的马克·卢茨（Mark Lutes）担任该专栏编辑。
